Table 4. Clinical outcome before and after surgical treatment in LPFH and non-LPFH groups.
| Before CD surgery | After CD surgery | P value (II) | |
|---|---|---|---|
| VAS | |||
| LPFH group (n = 23) | 4.6 ± 1.8 | 1.6 ± 0.8 | 0.000 |
| non-LPFH group (n = 28) | 6.1 ± 1.7 | 2.1 ± 0.9 | 0.000 |
| P value (I) | 0.003 | 0.055 | |
| HHS | |||
| LPFH group (n = 23) | 77.4 ± 5.6 | 87.5 ± 5.2 | 0.000 |
| non-LPFH group (n = 28) | 67.0 ± 6.7 | 83.5 ± 5.1 | 0.000 |
| P value (I) | 0.000 | 0.008 | |
| LPFH group (n = 23) | non-LPFH group (n = 28) | P value (III) | |
| Clinical outcome* | |||
| Improved | 91.3% (21/23) | 82.1% (23/28) | 0.436 |
| Unchanged | 8.7% (2/23) | 14.3% (4/28) | 0.678 |
| Worsened | 0% (0/23) | 3.6% (1/28) | 1.000 |
Note: CD, Core decompression; VAS, visual analogue scale; HHS, Harris hip score.
P value (I): comparison of data between LPFH group and non-LPFH group for pain score and Harris hip score.
P value (II): comparison of data before and after CD within the same group.
P value (III): comparison of data between LPFH group and non-LPFH group for clinical outcome.
*Clinical outcome [26]: ‘Improved’ was defined when significant improvements in pain and function of the affected hip were noted after treatment. ‘Unchanged’ was defined when very little or no changes were noted after treatment. ‘Worsened’ was defined when more pain and less function were noted after treatment.